Adverum Bio’s shares plummet after patient in gene therapy study loses vision

eye, vision

Adverum Biotechnologies reported that a diabetic macular edema patient treated with the biotech’s experimental gene therapy developed complications, including blindness, in the treated eye. The company has unmasked the study and is trying to identify potential risks to other patients.